ReviewFrontiers in oncology2026
Early multi-cancer detection using liquid biopsy: emerging biomarkers and clinical strategies.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liquid biopsy has become a revolutionary method for the early detection of cancer as a non-invasive technology that can assess circulating tumor material in biofluids. Liquid biopsy allows dynamic monitoring of tumor evolution, genetic changes and treatment responses, which is different from traditional tissue biopsy which offers a static and potentially narrow view of tumor biology. This mini-review will summarize the rapidly evolving future of circulating biomarkers (circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), microRNAs, proteins, exosomes and epigenetic fingerprints), with their potential for early multi-cancer biomarkers, and their integration into early detection. The analytical sensitivity of liquid biopsy has expanded dramatically through technologies such as next-generation sequencing (NGS), digital PCR, and advanced proteomics. In addition, data collection has been enhanced through machine learning for increased predictive performance and the identification of new biomarkers. This review discusses clinical performance between liquid and tissue biopsy and the value of combined biomarker methods to improve accuracy for the detection of early disease. Finally, future directions will be presented to identify new methods of integration, improved costs and the establishment of early detection programs at the population scale.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.